Page last updated: 2024-08-26

wr 1065 and Neoplasms

wr 1065 has been researched along with Neoplasms in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bykov, VJ; Selivanova, G; Wiman, KG1
Koukourakis, MI1
Capizzi, R1
Capizzi, RL1
Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D1
Grdina, DJ; Nagy, B; Sigdestad, CP1
Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C1

Reviews

5 review(s) available for wr 1065 and Neoplasms

ArticleYear
Small molecules that reactivate mutant p53.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:13

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ellipticines; Gene Expression Regulation, Neoplastic; Genes, p53; Genetic Therapy; Humans; Mercaptoethylamines; Molecular Chaperones; Mutation; Neoplasms; Pyrimidines

2003
Amifostine: is there evidence of tumor protection?
    Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18

    Topics: Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dogs; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Models, Animal; Neoplasms; Organoplatinum Compounds; Radiation Injuries; Radiation-Protective Agents; Rats; Sarcoma

2003
Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
    Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 8

    Topics: Amifostine; Animals; Antineoplastic Agents; Cells; Combined Modality Therapy; Humans; Mercaptoethylamines; Neoplasms; Premedication

1996
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
    Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 7

    Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Experimental; Prodrugs; Protective Agents; Radiation-Protective Agents; Tumor Cells, Cultured

1999
Radioprotectors in treatment therapy to reduce risk in secondary tumor induction.
    Pharmacology & therapeutics, 1988, Volume: 39, Issue:1-3

    Topics: Amifostine; Animals; Cell Transformation, Neoplastic; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Radiation-Induced; Radiation-Protective Agents

1988

Trials

1 trial(s) available for wr 1065 and Neoplasms

ArticleYear
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
    Cancer, 2001, Aug-15, Volume: 92, Issue:4

    Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure

2001

Other Studies

1 other study(ies) available for wr 1065 and Neoplasms

ArticleYear
Human pharmacokinetics of WR-2721.
    International journal of radiation oncology, biology, physics, 1986, Volume: 12, Issue:8

    Topics: Amifostine; Humans; Kinetics; Mercaptoethylamines; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents; Tissue Distribution

1986